Advancing the global public health agenda for NAFLD: a consensus statement
Open accessThe DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease with a substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts develop consensus statements and recommendations addressing a broad range of topics on NAFLD to raise awareness and spur action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationExpanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Research works printed but not linked: 2
- Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).
- Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).
Cited by
Items 401–500 of 807
Longo, L., Marschner, R. A., de Freitas, L. B. R., de Bona, L. R., Behrens, L. M. P., Pereira, M. H. M., de Souza, V. E. G., Leonhard, L. C., Zanettini, G., Pinzon, C. E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136839 · Cited by 10
Schreiner, A. D., Zhang, J., Moran, W. P., Koch, D., Marsden, J. E., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.002 · Cited by 8
Stigma in steatotic liver disease: A survey of patients from Saudi Arabia
Alqahtani, S. A., Alswat, K., Mawardi, M., Sanai, F. M., Abaakhail, F., Alghamdi, S. A., Al-hamoudi, W., Nader, F., Stepanova, M., & Younossi, Z. M. (2024) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_122_24 · Cited by 8
Self-citationTea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study
Lu, C., Ke, L., Mentis, A. A., Zhang, Q., Wang, Z., & Wang, Z. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100322 · Cited by 8
“NAFLD currently poses huge medical and societal burdens to countries around the world, especially in western countries [1,31].”
BackgroundHakkak, R., Korourian, S., Li, W., Spray, B. J., Twaddle, N. C., Randolph, C. E., Børsheim, E., & Robeson, M. S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1487859 · Cited by 8
Tianqi, Y., Zhou, Y., Wu, X., Fang, Z., & Liu, C. (2025) · Nature and Science of Sleep · doi:10.2147/nss.s524675 · Cited by 9
Self-citationKhalifa, O., Ouararhni, K., Errafii, K., Alajez, N. M., & Arredouani, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411606 · Cited by 8
“Therefore, NAFLD is a significant public health issue [9] but presently has no approved pharmacotherapy.”
BackgroundSerum Ferritin and Non-alcoholic Fatty Liver Disease: A Meta-analysis and Systematic Review
Yan, J., Guan, T., Guo, M., & Liu, J. (2023) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2023.22453 · Cited by 12
Zhang, X., Huangfu, Z., & Wang, S. (2023) · Endocrine · doi:10.1007/s12020-023-03467-8 · Cited by 8
“Arrhythmia, thrombotic disease, cerebrovascular disease, peripheral vascular disease (PVD), coronary artery disease (CAD), heart failure (HF) and other circulatory diseases such as myocarditis, congenital heart diseases, are all included under this term [4].”
BackgroundQi, Z., Le, S., Cheng, R., Du, X., Zhao, C., Zhang, Z., Zhang, X., Feng, L., Schumann, M., Mao, L., et al. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003388 · Cited by 8
“It is well known that NAFLD is a complex metabolic disease, closely re-lated to obesity (46) and insulin sensitivity (47).”
BackgroundCastillo, M. F., Salgado-Canales, D., Arrese, M. A., Francisco Barrera, M., & Mikhailidis, D. P. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611285401240110074530 · Cited by 9
Self-citationHe, L., Tiemuerniyazi, X., Yang, Z., Huang, S., Chen, L., Nan, Y., Song, Y., & Feng, W. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae336 · Cited by 7
Ma, H., Zhang, W., Zhao, Z., Jin, S., Li, L., Zong, R., Li, W., Zhang, Z., Cui, S., Pan, Y., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1604991 · Cited by 7
“It is characterized by excessive hepatic lipid accumulation in the absence of signi fi cant alcohol consumption, steatogenic medications, or viral infections and may progress from simple nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which can lead to fi brosis, cirrhosis, and hepatocellular car…”
InfluentialCrespo, J., Iruzubieta, P., & Fernández‐Rodríguez, C. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.11339/2025 · Cited by 11
Self-citationIslam, K., Kongsomboonchoke, P., Chayanupatkul, M., Tumkosit, M., Chattranukulchai, P., Prombutara, P., & Tangkijvanich, P. (2025) · Nutrients · doi:10.3390/nu17172759 · Cited by 7
“Indeed, CVD, particularly coronary artery disease, is a significant cause of morbidity and mortality in patients with MASLD [5].”
Ciurea, N.-A., Pantea, C. M., Grama, P., Kosovski, I.-B., & Bataga, S. M. (2025) · Medicina · doi:10.3390/medicina61091527 · Cited by 7
“The condition carries a significant risk of progression to steatohepatitis, fibrosis, cirrhosis, or even hepatocellular carcinoma in the absence of timely medical or nutritional intervention [1].”
The role of rare ginsenosides in the prevention and treatment of liver diseases
Zhang, Y., Liu, Y., Wei, Y., Ren, Z., Jin, Y., & Li, G. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120666 · Cited by 9
Lazarus, J. V., Agirre‐Garrido, L., Miralles‐Sanchez, J. E., Manolas, M. I., Tacke, F., Villela‐Nogueira, C. A., Al‐Omar, H. A., Alqahtani, S. A., Alzubaidi, L. M. Y., Bansal, M. B., et al. (2025) · Liver International · doi:10.1111/liv.70390 · Cited by 7
Self-citationGeng, Y., Li, Y.-F., Liu, G., & Jiao, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-81120-8 · Cited by 7
Gillet, R., Tomás Cerda, G., Brañes, M. C., & Valenzuela, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020564 · Cited by 8
“, no available pharmacology has been spe-cifically approved for MAFLD treatment, and the available recommendations consist of lifestyle changes such as diet, weight loss, and physical activity [37].”
Unsupervised Test-Time Adaptation for Hepatic Steatosis Grading Using Ultrasound B-Mode Images
Vianna, P., Mehrbod, P., Chaudhary, M., Eickenberg, M., Wolf, G., Belilovsky, E., Tang, A., & Cloutier, G. (2025) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2025.3555180 · Cited by 7
“The early detection of MAFLD is poised to reduce the burden on healthcare systems [4], [5].”
Advancing Liver Cancer Prevention for American Indian Populations in Arizona: An Integrative Review
Godfrey, T. M., Villavicencio, E. A., Barra, K., Sanderson, P. R., Shea, K., Sun, X., & Garcia, D. O. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063268 · Cited by 7
“Estimates in the prevalence of NAFLD varies between and within regions of the world, with the highest prevalence in the Middle East (32%) and South America (30%) and the lowest in Africa (13%) [13].”
BackgroundGracen, L., Hayward, K. L., Aikebuse, M., Russell, A. W., O’Beirne, J. P., McPhail, S., Irvine, K. M., Williams, S., Valery, P. C., & Powell, E. E. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07808-7 · Cited by 10
“There was unanimous agreement from the consensus group that there are “both economic and social arguments for taking action on NAFLD” and “early intervention could help reduce the burden of disease, associated healthcare costs and economic losses” [45].”
BackgroundKandhi, R., Variya, B. C., Ramanathan, S., & Ilangumaran, S. (2022) · The Anatomical Record · doi:10.1002/ar.25039 · Cited by 8
Carpino, G., Overi, D., Onori, P., Franchitto, A., Cardinale, V., Alvaro, D., & Gaudio, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710065 · Cited by 7
“Nonalcoholic fatty liver disease (NAFLD), or metabolic-associated fatty liver disease (MAFLD) is a chronic liver disease defined by the presence of lipid accumulation within hepatocytes without excessive alcohol consumption [1,2].”
BackgroundSelf-citationLCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine
He, H., Chai, X., Li, J., Li, C., Wu, X., Ye, X., Ma, H., & Li, X. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121595 · Cited by 7
Niu, Z., Liu, J., Peng, H., Wu, X., Zheng, X., Yao, S., & Xu, C. (2024) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2024.02.003 · Cited by 8
Brozat, J. F., Ntanios, F. Y., Malhotra, D., Dagenais, S., Katchiuri, N., Emir, B., & Tacke, F. (2023) · Liver International · doi:10.1111/liv.15815 · Cited by 7
Self-citationMurphy, M., Dijkstra, H. P., Ardern, C. L., & Mkumbuzi, N. S. (2025) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-109680 · Cited by 7
Lin, G., Ou, W., Yang, J., Chen, D., Wang, Y., Wu, A., Gao, L., Qu, W., Lin, C., & Liang, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1586212 · Cited by 8
El‐Kassas, M., & Sanai, F. M. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_247_25 · Cited by 6
Self-citationWang, M., Wuyun, Q., Lian, D., Xu, G., Zhu, G., & Zhang, N. (2025) · Medicine · doi:10.1097/md.0000000000044527 · Cited by 6
“[8] The global burden of disease (GBD) is a systematic framework for evaluating health conditions and risk factors associated with diseases globally across various nations and regions.”
Zhou, Y., Dai, Y., Qin, M., Li, Y., Shi, L., Chen, H., Fan, H., Yu, Y., Guo, L., & Xiong, J. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156462 · Cited by 6
Locatelli, C., Karine, L. U. Z., de Andrade, S. F., Bellaver, E. H., Ogoshi, R. C. S., Centa, A., Assolini, J. P., Pont, G. C. D., & Creczynski‐Pasa, T. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010120 · Cited by 7
“The close association between MASLD and HCC suggests a potential progression from steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis, and malignancy, particularly in individuals with obesity and MetS [30].”
Wang, L. Y., & Wang, Y. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s593387 · Cited by 8
“18 Nevertheless, liver biopsy still has well-known limitations, including invasiveness, poor acceptability, potentially life-threatening complications, sampling variability and high cost.”
Ali, M. F., Ahmad, H., Maloth, A. K., Kumar, H., Ramadan, Y., Malik, M. S., Qadeer, T., Khan, M., Mohmand, M. S., Joshi, S., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02044-w · Cited by 6
“The COVID−19 pandemic has likely aggravated trends of NAFLD associated mortality among individuals with DM by interrupting routine man - agement of DM and liver disease, especially among high-risk populations with preexisting conditions [24].”
Mahmoudi, T., Ghorbani, D., Rezamand, G., Dehestan, N., Jeddi, G., Asadi, A., Nobakht, H., Dabiri, R., Farahani, H., Tabaeian, S. P., et al. (2023) · Personalized Medicine · doi:10.2217/pme-2022-0100 · Cited by 8
Mallmann, M. M., Strobel, R., Ivantes, C. A. P., Sakamoto, D. G., Duarte, M. L., & Pedroso, M. L. A. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2022-0138 · Cited by 6
Mathew, J. F., Panackel, C., Mathew, J., Ramesh, G. N., & John, N. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101407 · Cited by 7
Kim, G., Yu, T. Y., Jee, J. H., Bae, J. C., Kang, M., & Kim, J. H. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101534 · Cited by 6
Ghooray, D. T., Xu, M., Shi, H., McClain, C. J., & Song, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094836 · Cited by 6
Self-citationDing, Z., Zhang, J., & Choudhury, M. (2024) · Life · doi:10.3390/life14060729 · Cited by 9
“Nearly 20% of those with MASLD go on to develop MASH; additionally, more than 20% of those with MASH may develop liver cirrhosis [3].”
BackgroundNAMPT gene rs2058539 variant is a risk factor for nonalcoholic fatty liver disease
Nouri, S., Navari, M., Zarei, F., Rostami, M., Mahmoudi, T., Rezamand, G., Asadi, A., Nobakht, H., Dabiri, R., & Tabaeian, S. P. (2024) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230188 · Cited by 6
Álvares‐da‐Silva, M. R., Vargas, M. D. S., Rabie, S. M. S., Jonko, G., Riedel, P. G., Longo, L., Gonçalves, M. R., Luft, V. C., & Joveleviths, D. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101584 · Cited by 12
“A global study of 102 countries presented a similar picture, highlighting the lack of atten-281 tion to MASLD in health agendas [ 4].”
Wang, Z., Yu, S., Yang, B., Wang, P., Yang, Y., Bo, Y., & Wang, W. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.126570 · Cited by 6
Association of metabolic abnormalities and the risk of hepatic fibrosis
Fu, J., Yi, Y., Li, L., Shu, X., & Chang, Y. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00025-z · Cited by 6
Self-citationPérez-Díaz-del-Campo, N., Castelnuovo, G., Ferro, A., Caviglia, G. P., Rosso, C., Dileo, E., Guariglia, M., Armandi, A., Saba, F., Saracco, G. M., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003594 · Cited by 8
Self-citationJosol, V. J. D., Salvador, P. B. U., Cruz, L. L. A., Ornos, E. D. B., & Tantengco, O. A. G. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100527 · Cited by 7
Zhang, P., Cao, J., Liang, X., Su, Z., Zhang, B., Wang, Z., Xie, J., Chen, G., Chen, X., Zhang, J., et al. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024025 · Cited by 7
“Although only some people with NAFLD develop life-threatening diseases, including type II diabetes (T2D), liver fibrosis, cirrhosis, and even hepatocellular carcinoma [5–7], more than one-fourth of the global population suffers from NAFLD [8].”
Roy, A., De, A., Kulkarni, A. V., Jajodia, S., Goenka, U., Tewari, A., Sonthalia, N., & Goenka, M. K. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23063 · Cited by 6
Species differences of fatty liver diseases: comparisons between human and feline
Ling, L., Li, R., Xu, M., Zhou, J., Hu, M., Zhang, X., & Zhang, X.-J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2024 · Cited by 7
Bridging the gap: increasing MENA representation in MASLD clinical trials
El‐Kassas, M. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01081-9 · Cited by 6
“One of the fundamental barriers to MASLD management in MENA is the limited validation of non-invasive tests in the region 5 .”
Self-citationMa, W., Huang, J., Cai, B., Shao, M., Yu, X., Kjær, M. B., Lv, M., Zhong, X., Xu, S., Zhan, B., et al. (2026) · Liver International · doi:10.1111/liv.70823 · Cited by 6
Self-citationAlgorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting
Bech, K., Lindvig, K. P., Thiele, M. S., & Castéra, L. (2024) · Seminars in Liver Disease · doi:10.1055/s-0043-1778127 · Cited by 7
Self-citationBhadoria, A. S., Saxena, G., Pandey, P., Mehndiratta, A., Sadasivan, A., Gupta, R., Singh, P., & Nundy, S. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1536_23 · Cited by 6
Xu, R., Wu, J., Pan, J., Zhang, S., Yang, Y., Zhang, L., Zhou, W., Wu, N., Hu, D., Ji, G., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444561 · Cited by 6
Zheng, Y.-T., Tian-mei, X., Wu, C.-X., Cheng, J., & Li, L.-Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.798417 · Cited by 6
Nobakht, H., Mahmoudi, T., Rezamand, G., Tabaeian, S. P., Jeddi, G., Asadi, A., Farahani, H., Dabiri, R., Mansour‐Ghanaei, F., Kaboli, S. A., et al. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac039 · Cited by 6
Kopka, C. J., Pugliese, N., Brennan, P., & Lazarus, J. V. (2024) · Liver International · doi:10.1111/liv.15951 · Cited by 6
Self-citationZheng, Y., Xiong, Z., Zhao, L., Huang, C., Yong, Q., Fang, D., Liu, F., & Li, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0471 · Cited by 5
Li, Y. T., Pan, T., Wang, Y., Wang, G., & Wang, F. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.041 · Cited by 5
Hara, E., Ohshima, K., Takimoto, M., Bai, Y., Hirata, M., Zeng, W., Uomoto, S., Todoroki, M., Kobayashi, M., Kozono, T., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062709 · Cited by 5
“Nonalcoholic fatty liver disease (NAFLD) is a severe liver disease, globally affecting approximately 25% of the population and imposing a significant health burden along with widespread social and economic consequences [1].”
Laparoscopically confirmed endometriosis and the risk of incident NAFLD: a prospective cohort study
Huang, H., Liu, Z., Ruan, J., Fang, Z., & Xu, C. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01391-2 · Cited by 5
“Alongside the epidemic of obesity and type 2 diabetes, the disease burden of nonalcoholic fatty liver disease (NAFLD) is increasing dramatically [1].”
Chen, X., Fu, J., Jin, K., Yang, Z., Qian, Y., Mei, K., Wang, Y., Min, J., Du, Y., Zhu, Z., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1565298 · Cited by 5
Apodaka‐Biguri, M., Simão, A. L., González‐Romero, F., Mestre, D., Rodrigues, P. M., Aurrekoetxea, I., Gómez‐Santos, B., Buqué, X., Nieva‐Zuluaga, A., de Gauna, M. R., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001461 · Cited by 5
“[4] The high heterogeneity of patients with MASLD makes it challenging to find appropriate “ one fits all ” treatments, for which an accurate stratification of patients is even more critical.”
Li, M., Zhang, C., Ma, J., Zeng, B., Li, X., Zhao, X., Bi, X., Li, R., Gao, Q., Jiang, Y., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1710380 · Cited by 6
“Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other NCDs, such as obesity, diabetes, and cardiovascular diseases (5).”
Abdelhamed, W., Amin, M. A., Waked, I. A., & El‐Kassas, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i45.111643 · Cited by 7
Self-citationManna, L. B., Chatzakis, C., Ovadia, C., Williamson, C., & Nicolaides, K. H. (2025) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/j.lanogw.2025.100038 · Cited by 5
Athinarayanan, S. J., Wolfberg, A., Shanmugam, P., Hameed, B., & Bonacini, M. (2026) · Hepatology · doi:10.1097/hep.0000000000001713 · Cited by 5
“[4] The global economic burden is substantial, with a recent analysis estimating that the clinical, humanistic, and economic impact of MASH exceeds $300 billion annually across major countries, underscoring the cost of inaction.”
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 5
Self-citationCaussy, C., Telliam, C., Al-Nuaimi, B., Maynard, M., Dumortier, J., Zoulim, F., Disse, E., Colin, C., Levrero, M., & Moulin, P. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s407511 · Cited by 7
“These patients currently remain under-diagnosed, although they require specialized care, follow-up in hepatology and may potentially benefit from novel pharmacological therapies in the near future.(21,22) In addition, real world data will help to improve the accessibility of the NITs, providing a better insight into t…”
BackgroundLiu, Z., Zhang, W., Zhao, Z., Li, W., & Zhang, J. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421840 · Cited by 5
“NAFLD affects around a quarter of the global adult population, resulting in widespread social and economic implications.(1) As well as causing liver damage, NAFLD is also closely associated with metabolic disorders.”
Mahmoudi, T., Nouri, S., Zarei, F., Najafabadi, Z. N., Sanei, M., Sayedsalehi, S., Rezamand, G., Asadi, A., Dabiri, R., Nobakht, H., et al. (2023) · PubMed Central · doi:10.20945/2359-4292-2023-0017 · Cited by 8
“Although the very high prevalence of NAFLD (approximately a quarter of adults worldwide) has placed a heavy burden on the healthcare system, its etiology is still unresolved (1).”
Zhang, H., Sham, T.-T., Li, C., Wang, Y., Li, C., Cheng, K. K. Y., So, C.-P., Huang, Y.-Y., Chan, S., & Mok, D. K. (2023) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2023.100335 · Cited by 5
Mogna-Peláez, P., Romo‐Hualde, A., Riezu‐Boj, J. I., Milagro, F. I., Muñoz‐Prieto, D., Herrero, J. I., Elorz, M., Benito, A., Monreal, J. I., Tur, J. A., et al. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00998-6 · Cited by 5
Lara, I. P., Ortiz‐López, M. G., Bonilla‐Delgado, J., Pérez-Escobar, J., Godínez-Aguilar, R., Luévano‐Contreras, C., Espinosa-García, A. M., Duran, J. P., Alonso-Themann, P. G., Nolasco‐Quiroga, M., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101562 · Cited by 5
Alhazzani, W. A., AlMuhaidib, S., Alotaibi, H. F., AlOmaim, W. S., Alqahtani, R. S., Sanai, F. M., Abaalkhail, F. A., & Alqahtani, S. A. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_431_24 · Cited by 5
“[8,9] However, despite its growing prevalence, there has been no comprehensive examination of the research efforts on MASLD in Arab countries.”
Self-citationClaro, M. I., Viñals, C., Giménez, M., Perea, V., Granados, M., Serés‐Noriega, T., Blanco, J., Vinagre, I., Mesa, A., Milad, C., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112334 · Cited by 5
Challenges and opportunities in nonalcoholic steatohepatitis
Wang, X. (2022) · Medical Review · doi:10.1515/mr-2022-0024 · Cited by 5
Blaschke, S., Schad, N., Schnitzius, M., Pelster, K., & Mess, F. (2023) · Nutrients · doi:10.3390/nu15030648 · Cited by 5
“In addition, NAFLD is the hepatic manifestation of metabolic syndrome, being closely linked to other non-communicable diseases, such as diabetes mellitus [2], and increased cardiovascular and overall morbidity and mortality [7].”
A global research priority agenda to advance public health responses to fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Villota‐Rivas, M., Schattenberg, J. M., Wong, V. W., & Younossi, Z. M. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00603-7 · Cited by 6
Self-citationCross-talk between gut microbiota and liver steatosis: Complications and therapeutic target
Yao, Y., & Shen, Y. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0699 · Cited by 5
“[33] Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L,”
BackgroundArenas‐Pinto, A., Bakewell, N., Milinkovic, A., Williams, I. G., Vera, J. H., Post, F. A., Anderson, J., Beynon, M., O'Brien, A. J., Doyle, N., et al. (2023) · HIV Medicine · doi:10.1111/hiv.13540 · Cited by 5
Kobayashi, N., Tada, T., Nishimura, T., Matono, T., Yuri, Y., Takashima, T., Aizawa, N., Ikeda, N., Fukunishi, S., Hashimoto, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13994 · Cited by 6
Zhang, L., Xu, L., Rong, A., Cui, Y., Wang, L., Li, L., Han, X., Xiao, X., & Wu, H. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16676 · Cited by 5
A significant and persistent rise in the global burden of adolescent NAFLD and NASH estimated by BMI
Lin, X.-Y., Li, J.-M., Huang, L., Lin, L.-Y., Hong, M., Weng, S., & Pan, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1437432 · Cited by 5
Spotlight on liver macrophages for halting liver disease progression and injury
Khurana, A., Navik, U., Allawadhi, P., Yadav, P., & Weiskirchen, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2133699 · Cited by 5
“adult global population and 20–30% of patients with NAFLD progress to NASH [62].”
BackgroundTryndyak, V., Willett, R. A., Nagumalli, S. K., Li, D., Avigan, M., Beland, F. A., Rusyn, I., & Pogribny, I. P. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00225.2022 · Cited by 5
Predictive risk markers in alcoholism
Niemelä, O. J. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.05.002 · Cited by 5
Is liver fibrosis a risk factor for gynecological cancers?
Lonardo, A. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.56 · Cited by 5
Kalka, I. N., Hazzan, R., Yacovzada, N.-S., Igbaria, S., Segal, E., Weinberger, A., & Neeman, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-17534-9 · Cited by 4
Li, Y., Ye, X., & Chen, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1589245 · Cited by 4
“Furthermore, progression is associated with substantial health-care costs, socioeconomic losses and reduced quality of life (7).”
Huang, C., Chen, M., Sun, Y., Zhang, L., & Liu, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1689280 · Cited by 4
Bu, J., Mi, N., Liang, Z., Xie, P., Long, C., Yang, M., Yuan, J., Xia, B., Liu, A., Xiang, S., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004181 · Cited by 4
Liang, Q., Hu, H., Chen, X., Yang, S., Zhang, Y., Wu, Y., Wang, X., & Chen, H. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s556539 · Cited by 4
Njei, B. M., Al‐Ajlouni, Y. A., Tanih, D. N., Kanmounye, U. S., Boateng, S., Halwani, K. W., Nguefang, G., & Lim, J. K. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00741-0 · Cited by 4
“Up to 20% of affected individuals develop the more aggressive form, metabolic dysfunction–associated steatohepatitis (MASH), which is linked to increased risks of myocardial infarction, ischemic stroke, atrial fibrillation, and heart failure [1].”
Li, X., Jin, K., Fang, J., Ma, X., He, J., Lu, A., Jia, Z., & Shi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835197 · Cited by 4
“MASLD has emerged as a leading cause of chronic liver disease globally and is becoming a predominant indication for liver transplantation due to its complications of cirrhosis and HCC (6).”
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 6
“As a major public health challenge, NAFLD/MASLD urgently requires the translation of mechanistic discoveries into accessible interventions (193).”
Baragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 6
Liver Fibrosis is Associated with Clinical Outcomes in Patients with Intracerebral Hemorrhage
Wang, J., Bian, L., Wang, A., Zhang, X., Wang, D., Jiang, R., Wang, W., Ju, Y., Lu, J., & Zhao, X. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s375532 · Cited by 4
“The overall incidence rate of NAFLD ranges from 23% to 25% and creates substantial burdens on families and society.(1) In the setting of global obesity, the prevalence of NAFLD has increased steadily over recent years, affecting both adults and children.”
Background
Metadata
- Authors
- Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagström, H., Huang, T. T.-K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gómez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W.-S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., the NAFLD Consensus Consortium, Åberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W.-K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. D. A. S., de Ledinghen, V., DelPrato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J.-G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B.-B., Grønbæk, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J.-H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C.-J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vázquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Gonçalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suárez, J. J., Sheriff, D. S., Sung, K.-C., Swain, M., Tacke, F., Taheri, S., Tan, S.-S., Tapper, E. B., Yki-Järvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M.-L., Zheng, K. I., Zeybel, M., & Zheng, M.-H.
- Affiliations
- Barcelona Institute for Global Health (ES)
- European Association for the Study of the Liver (CH)
- NIHR Newcastle Biomedical Research Centre (GB)
- Pontificia Universidad Católica de Chile (CL)
- University College London Hospitals NHS Foundation Trust (GB)
- Marqués de Valdecilla University Hospital (ES)
- Veterans Health Administration (US)
- University of Washington (US)
- University of Antwerp (BE)
- The University of Sydney (AU)
- Karolinska Institutet (SE)
- City University of New York (US)
- King Fahd Hospital of the University (SA)
- Institute of Liver and Biliary Sciences (IN)
- University of California San Diego (US)
- University of California, Berkeley (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Makerere University (UG)
- Université Paris Cité (FR)
- Northwestern University (US)
- The Graduate Center, CUNY (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- The Royal Free Hospital (GB)
- University of Milan (IT)
- Chinese University of Hong Kong (HK)
- Marmara University (TR)
- Inova Health System (US)
- University of Helsinki (FI)
- The University of Western Australia (AU)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- King Saud University (SA)
- Sapienza University of Rome (IT)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Health and Allied Sciences (GH)
- University of KwaZulu-Natal (ZA)
- Mongolian National University of Medical Sciences (MN)
- Ministry of Health of the Republic of Uzbekistan (UZ)
- University of Virginia (US)
- University of Pittsburgh (US)
- Ahfad University for Women (SD)
- Vita-Salute San Raffaele University (IT)
- University of Turin (IT)
- University of Padua (IT)
- University of Southampton (GB)
- Inserm (FR)
- University of the West Indies (BS)
- Universidad de Buenos Aires (AR)
- Union Hospital (HK)
- University of Malaya (MY)
- Kangbuk Samsung Hospital (KR)
- IRCCS Ospedale San Raffaele (IT)
- University of Otago (NZ)
- Harvard University (US)
- University of Kelaniya (LK)
- University of Pisa (IT)
- St. Paul's Hospital Millennium Medical College (ET)
- University of Dundee (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- World Heart Federation (CH)
- Linköping University (SE)
- National Ribat University (SD)
- Cairo University hospitals (EG)
- Shanghai Jiao Tong University (CN)
- Medical University of Białystok (PL)
- Minia University (EG)
- Virginia Commonwealth University (US)
- University of Indonesia (ID)
- Carol Davila University of Medicine and Pharmacy (RO)
- Singapore General Hospital (SG)
- Aarhus University Hospital (DK)
- Aga Khan University (PK)
- British Liver Trust (GB)
- Princess Alexandra Hospital (AU)
- Kuwait University (KW)
- Hlabisa Hospital (ZA)
- Catholic University of Korea (KR)
- National Academy of Medical Sciences (NP)
- National Hospital Organization Takasaki General Medical Center (JP)
- Baylor College of Medicine (US)
- National Taiwan University Hospital (TW)
- Kurume University (JP)
- Jordan University of Science and Technology (JO)
- Yonsei University (KR)
- Université d'Abomey-Calavi (BJ)
- Maastricht University Medical Centre (NL)
- The University of Tokyo (JP)
- Institut Pasteur de Bangui (CF)
- Denver Public Library (US)
- Hôpital La Rabta (TN)
- University Hospital of Bern (CH)
- Columbia University (US)
- Drexel University (US)
- Wilton Park (GB)
- Boston University (US)
- University of Tehran (IR)
- Bangladesh Medical University (BD)
- University of Bologna (IT)
- Centro Hospitalar Lisboa Norte (PT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital St. Ivan Rilski (BG)
- University of Kinshasa (CD)
- Favaloro Foundation (AR)
- Yokohama City University (JP)
- Universidad Autónoma de Nuevo León (MX)
- Ss. Cyril and Methodius University in Skopje (MK)
- St. James's Hospital (IE)
- Ljubljana University Medical Centre (SI)
- Guy's Hospital (GB)
- University of the Philippines Manila (PH)
- Lagos State University (NG)
- National and Kapodistrian University of Athens (GR)
- University Health Network (CA)
- Universidade Nova de Lisboa (PT)
- University of Palermo (IT)
- NYU Langone Health (US)
- World Obesity Federation (GB)
- University of British Columbia (CA)
- Center for Disease Analysis (US)
- Alfred Health (AU)
- Düsseldorf University Hospital (DE)
- University of Leeds (GB)
- Tartu University Hospital (EE)
- Kyrgyz State Medical Academy (KG)
- Saint Joseph University (LB)
- McGill University Health Centre (CA)
- Yotsuya Medical Cube (JP)
- Baker Heart and Diabetes Institute (AU)
- King's College London (GB)
- Tel Aviv University (IL)
- Children's Memorial Health Institute (PL)
- Hospital Universitario de La Princesa (ES)
- University of Cape Town (ZA)
- Arabian Gulf University (BH)
- Universidad San Francisco de Quito (EC)
- University of Calgary (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Weill Cornell Medical College in Qatar (QA)
- Hospital Selayang (MY)
- University of Michigan (US)
- University of Southern Denmark (DK)
- University of Malawi (MW)
- Riga East University Hospital (LV)
- University of Puerto Rico, Medical Sciences Campus (PR)
- Medical University of Vienna (AT)
- Chulalongkorn University (TH)
- Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
- Vilnius University Hospital Santariskiu Klinikos (LT)
- Haraldsplass Diakonale Sykehus (NO)
- National Liver Institute (EG)
- University of Edinburgh (GB)
- Stanford Medicine (US)
- Cincinnati Children's Hospital Medical Center (US)
- National University of Singapore (SG)
- Kaohsiung Medical University (TW)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Koç University (TR)
- Corresponding author
- Lazarus, Jeffrey V.
- ORCID
- Lazarus, Jeffrey V.
- Mark, Henry E.
- Anstee, Quentin M.
- Arab, Juan Pablo
- Batterham, Rachel L.
- Castera, Laurent
- Cortez-Pinto, Helena
- Crespo, Javier
- Cusi, Kenneth
- Dirac, M. Ashworth
- Francque, Sven
- George, Jacob
- Hagström, Hannes
- Huang, Terry T.-K.
- Ismail, Mona H.
- Sarin, Shiv Kumar
- Loomba, Rohit
- Miller, Veronica
- Newsome, Philip N.
- Ninburg, Michael
- Ocama, Ponsiano
- Ratziu, Vlad
- Rinella, Mary
- Romero, Diana
- Romero-Gómez, Manuel
- Schattenberg, Jörn M.
- Tsochatzis, Emmanuel A.
- Valenti, Luca
- Wong, Vincent Wai-Sun
- Yilmaz, Yusuf
- Younossi, Zobair M.
- Åberg, Fredrik
- Adams, Leon
- Naamani, Khalid Al
- Allen, Alina M.
- Alqahtani, Saleh A.
- Alswat, Khalid
- Alvaro, Domenico
- Andrade, Raúl J.
- Arrese, Marco
- Awuku, Yaw Asante
- Baatarkhuu, Oidov
- Bakieva, Shokhista
- Basu, Rita
- Bataller, Ramon
- Bedri, Shahinaz
- Bosi, Emanuele
- Bugianesi, Elisabetta
- Burra, Patrizia
- Byrne, Christopher D.
- Carrieri, Patrizia
- Chan, Henry Lik Yuen
- Chan, Wah-Kheong
- Chang, Yoosoo
- Colombo, Massimo
- Coppell, Kirsten J.
- Corey, Kathleen
- Cryer, Donna
- Dassanayake, Anuradha
- Desalegn, Hailemichael
- Dillon, John
- Duseja, Ajay
- Ekstedt, Mattias
- Elsanousi, Osama M.
- Esmat, Gamal
- Fan, Jian-Gao
- Flisiak, Robert
- Fouad, Yasser
- Fuchs, Michael
- Gani, Rino A.
- Gerber, Lynn
- Gheorghe, Liana
- Goh, George Boon-Bee
- Grønbæk, Henning
- Hamid, Saeed
- Hickman, Ingrid J.
- Hocking, Samantha L.
- Jamal, Mohammad H.
- Jepsen, Peter
- Song, Myeong Jun
- Kakizaki, Satoru
- Kanwal, Fasiha
- Kao, Jia-Horng
- Kaplan, Lee
- Kawaguchi, Takumi
- Khader, Yousef
- Kim, Seung Up
- Kodjoh, Nicolas
- Koek, Ger
- Koike, Kazuhiko
- Komas, Narcisse Patrice
- Korenjak, Marko
- Kugelmas, Marcelo
- Labidi, Asma
- Lange, Naomi F.
- Lavine, Joel E.
- Lazo, Mariana
- Lee, Nancy
- Lesmana, Cosmas Rinaldi A.
- Liu, Chun-Jen
- Long, Michelle T.
- Malekzadeh, Reza
- Mahtab, Mamun Al
- Marchesini, Giulio
- Marinho, Rui
- Vázquez, Sophia E. Martínez
- Nlombi, Charles Mbendi
- Musso, Carla
- Nakajima, Atsushi
- Norris, Suzanne
- Oben, Jude
- Ong, Janus P.
- Onyekwere, Charles
- Papatheodoridis, George
- Paruk, Imran
- Patel, Keyur
- Macedo, M. Paula
- Figueroa, Marlene Pérez
- Hofmann, Wolf Peter
- Petta, Salvatore
- Puri, Puneet
- Pan, Calvin Q.
- Ralston, Johanna
- Ramji, Alnoor
- Razavi, Homie
- Roberts, Stuart
- Roden, Michael
- Rowe, Ian A.
- Sadirova, Shakhlo
- Sebastiani, Giada
- Seki, Yosuke
- Shaw, Jonathan E.
- Sheron, Nick
- Shibolet, Oren
- Silva, Marcelo
- Socha, Piotr
- Soriano, Joan
- Spearman, C. Wendy
- Sridharan, Kannan
- Sheriff, Dhastagir Sultan
- Sung, Ki-Chul
- Swain, Mark
- Tacke, Frank
- Taheri, Shahrad
- Tan, Soek-Siam
- Tapper, Elliot B.
- Thiele, Maja
- Shawa, Isaac Thom
- Tolmane, Ieva
- Torres, Esther A.
- Trauner, Michael
- Treeprasertsuk, Sombat
- Turcanu, Adela
- Valantinas, Jonas
- Vesterhus, Mette
- Waked, Imam
- Wild, Sarah H.
- Wong, Robert J.
- Xanthakos, Stavra
- Yu, Ming-Lung
- Zheng, Kenneth I.
- Zheng, Ming-Hua
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-10-27
- Volume
- 19
- Issue
- 1
- Pages
- 60-78
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3208129759
- Cited by
- 757
- References
- 193
- Citations by year
- 2026: 100 · 2025: 156 · 2024: 163 · 2023: 201 · 2022: 127 · 2021: 9
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Falk Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- City University of New York
- Medpace
- Regeneron Pharmaceuticals
- European Federation of Pharmaceutical Industries and Associations
- Arrowhead Pharmaceuticals
- Medicines Company
- Galecto
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research (RP-2015-06-005)
- Rosetrees Trust
- Novo Nordisk
- Astellas Pharma
- Shionogi
- European Association for the Study of the Liver
- Novo Nordisk Fonden (NNF18OC0054612)
- Servier
- Julius Clinical
- Genentech
- Allergan
- Novartis Pharma
- Takeda Pharmaceuticals International
- Sanofi-Aventis Deutschland
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, public health policy, global health agenda, metabolic syndrome, non-communicable diseases, obesity, health system response, Delphi consensus
- MeSH terms
- Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.